SAD 1 : Approvisionnement MPUP et AC / Développement / Fabrication / Importation
Original notice title
France – Pharmaceutical products – Marché visant l’achat de matières premières à usage pharmaceutique, le développement, la fabrication, les prestations associées, et l’importation de médicaments pour le compte de l’Établissement pharmaceutique (EP) de l’AP-HP ainsi que, le cas échéant, la distribution pharmaceutique réalisée par le fabricant ou l’opérateur admis dans le marché, dans le cadre de la feuille de route du médicament (
Opportunity Score
Why this score?
Opportunity
55 / 100
Complexity
85 / 100
Risk factors
Critical details (value, deadlines, criteria) are absent from the notice, hindering bid preparation and risk assessment.
Combination of DPS and framework agreement with a restricted procedure may involve complex rules and phased evaluations.
Restricted procedure — pre-qualification required
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (AP-HP)
- Country
- France
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Feb 15, 2038
Overview
Moderate opportunityKey Facts
- Dynamic Purchasing System (DPS)
- Supplies contract
- 1 lot
- Duration 12 YEAR
- Purchase of pharmaceutical raw materials for pharmaceutical use
- Development, manufacturing, and importation of medicines
Show full summary
This restricted procedure establishes a 12-year Dynamic Acquisition System (DPS) combined with a framework agreement for the purchase of pharmaceutical raw materials, development, manufacturing, importation, and distribution of medicines for AP-HP's pharmaceutical establishment. Only one lot is identified. Submission is electronic and in French. No estimated value, submission deadline, or award/selection criteria are provided in the notice; these are expected in the full procurement documents.
Risks
Critical details (value, deadlines, criteria) are absent from the notice, hindering bid preparation and risk assessment.
Combination of DPS and framework agreement with a restricted procedure may involve complex rules and phased evaluations.
Restricted procedure — pre-qualification required
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Restricted procedure (two-stage: request to participate then tender)
- Dynamic Acquisition System (DPS) and framework agreement combined
Administrative
- Electronic submission required via Open portal
Requirements may be incomplete.
Buyer
Location
PARIS, FRA
Website
Buyer profile
Identifier
26750045201928
Activity
Health
Lots (1)
LOT-0001
SAD 1 : Approvisionnement MPUP et AC / Développement / Fabrication / Importation
Covers the purchase of pharmaceutical raw materials, development, manufacturing, associated services, importation of medicines, and, where applicable, distribution by the manufacturer or operator admitted to the market.
Location
Duration
Category
Award details
Marché visant l’achat de matières premières à usage pharmaceutique, le développement, la fabrication, les prestations associées, et l’importation de médicaments pour le compte de l’Établissement pharmaceutique (EP) de l’AP-HP ainsi que, le cas échéant, la distribution pharmaceutique réalisée par le fabricant ou l’opérateur admis dans le marché, dans le cadre de la feuille de route du médicament (
Show original TED data
Original TED description
Marché visant l’achat de matières premières à usage pharmaceutique, le développement, la fabrication, les prestations associées, et l’importation de médicaments pour le compte de l’Établissement pharmaceutique (EP) de l’AP-HP ainsi que, le cas échéant, la distribution pharmaceutique réalisée par le fabricant ou l’opérateur admis dans le marché, dans le cadre de la feuille de route du médicament (
Procurement Details
- Publication date
- 11 Feb 2026
- Languages
- French
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 102801-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
55 / 100
Complexity
85 / 100
Risk factors
Critical details (value, deadlines, criteria) are absent from the notice, hindering bid preparation and risk assessment.
Combination of DPS and framework agreement with a restricted procedure may involve complex rules and phased evaluations.
Restricted procedure — pre-qualification required
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications